---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-219610"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2026-05-12T20:31:11+00:00"
generated_at: "2026-05-12T20:32:41.032819+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Inhibikase Q1 2026 net loss $16.4M; first patient enrolled in Phase 3 PAH study IMPROVE-PAH

## Summary
- Net loss $16.4M ($0.10 EPS) vs $13.7M ($0.15) in Q1 2025; cash & equivalents $170.4M as of Mar 31, 2026.
- First patient enrolled in registrational Phase 3 IMPROVE-PAH study for IKT-001 in PAH; EMA approved 12 EU countries, total 16 countries.
- R&D expenses $10.8M (incl. one-time non-cash $7.4M from CorHepta acquisition in prior year); SG&A $7.4M.
- Upcoming presentations at ATS May 17 and 20, 2026 on safety/tolerability/PK and preclinical efficacy of IKT-001.

## SEC filing metadata
- accession: 0001193125-26-219610
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2026-05-12T20:31:11+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312526219610/0001193125-26-219610-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312526219610/d119997d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-219610
- JSON: https://secwatch.observer/filing/0001193125-26-219610.json
- Plain text: https://secwatch.observer/filing/0001193125-26-219610.txt

## Key facts
- Earnings Releases
  Inhibikase Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income $16.4 million, or $0.10 per share, EPS $0.10 per share.
  - Period: the quarter ended March 31, 2026
  - Net income: $16.4 million, or $0.10 per share
  - EPS: $0.10 per share
  - Result: reported results
  source text: Net loss for the quarter ended March 31, 2026, was $16.4 million, or $0.10 per share, compared to a net loss of $13.7 million, or $0.15 per share in the quarter ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312526219610/0001193125-26-219610-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.